Scholarlink

<p>Paclitaxel-induced peripheral neuropathy (PIPN) is a frequent, dose-limiting toxicity that affects up to 70% of patients undergoing paclitaxel-based chemotherapy. Its pathophysiology involves disrupted microtubule dynamics, mitochondrial dysfunction, altered calcium signalling, and neuroinflammation. Current treatment strategies for the management of PIPN are limited and underscore the urgent need to identify novel molecular targets to mitigate its adverse effects. Recent advances in molecular and neurological research highlight potential molecular targets including toll-like receptors (TLRs), transient receptor potential (TRP) channels, transcriptional regulators like peroxisome proliferator-activated receptor gamma co-activator 1 α (PGC-1α), and inflammatory cytokines. Epigenetic modulators and non-coding RNAs also hold significant potential as therapeutic agents in the management of PIPN. This review summarizes these emerging targets and explores therapeutic agents currently in preclinical and clinical development, aiming to guide future personalized strategies for PIPN management. <b>(</b>Figure created with BioRender.com and received the publishing license.)</p> Graphical abstract <p>(Figure created with BioRender.com and received the publishing license.)</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Emerging targets and translational challenges in treating paclitaxel-induced peripheral neuropathy

  • 期刊论文

  • 发表日期：

    2025年8月18日

查看全文
  • Sivadas Swathi Krishna,
  • Nandana Shaji,
  • Nandana V. Kumar,
  • Aiswarya Das,
  • Sabitha Mangalath,
  • Lalitha Biswas,
  • Keechilat Pavithran

摘要

Paclitaxel-induced peripheral neuropathy (PIPN) is a frequent, dose-limiting toxicity that affects up to 70% of patients undergoing paclitaxel-based chemotherapy. Its pathophysiology involves disrupted microtubule dynamics, mitochondrial dysfunction, altered calcium signalling, and neuroinflammation. Current treatment strategies for the management of PIPN are limited and underscore the urgent need to identify novel molecular targets to mitigate its adverse effects. Recent advances in molecular and neurological research highlight potential molecular targets including toll-like receptors (TLRs), transient receptor potential (TRP) channels, transcriptional regulators like peroxisome proliferator-activated receptor gamma co-activator 1 α (PGC-1α), and inflammatory cytokines. Epigenetic modulators and non-coding RNAs also hold significant potential as therapeutic agents in the management of PIPN. This review summarizes these emerging targets and explores therapeutic agents currently in preclinical and clinical development, aiming to guide future personalized strategies for PIPN management. (Figure created with BioRender.com and received the publishing license.)

Graphical abstract

(Figure created with BioRender.com and received the publishing license.)